サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1136912

排卵障害診断の世界市場-2022-2029

Global Ovulation Disorder Diagnosis Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
排卵障害診断の世界市場-2022-2029
出版日: 2022年10月13日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

排卵障害診断市場の成長は、計画妊娠の増加、出生率の低下、および一般市民のさまざまな排卵障害に対する意識の高まりによってもたらされる

2型糖尿病患者における多嚢胞性卵巣症候群（PCOS）の有病率が市場成長の原動力となる見込み

多嚢胞性卵巣症候群（PCOS）は、心血管、代謝、心理的要因に関連する一般的な代謝および内分泌生殖器疾患であり、世界の女性の約7％が罹患していると言われています。2022年8月にFrontiers in Endocrinologyに掲載された論文によると、糖尿病（DM）は世界の公衆衛生上の懸念事項となっています。2021年に世界で約5億3,700万人の成人（20～79歳）がDMを発症しており、そのほとんどが若年層です。現在、より若い年齢で2型DM（T2DM）を発症する患者さんが増えており、女性のT2DM患者さんは生殖期に罹患することが多くなっています。T2DM女性患者の生殖機能障害は、慎重に増加しています。T2DMを持たない患者さんと比較して、T2DMを持つ患者さんは月経障害や多嚢胞性卵巣などの臨床的変化をより多く示しています。これは、黄体形成ホルモンとインスリンの協力によって誘発される細胞内アンドロゲンレベルの上昇と関連している可能性があります。

また、PCOSは、2型糖尿病における内因性インスリン抵抗性と高インスリン血症により卵巣顆粒膜細胞が刺激され、小卵胞の成長と数が促進されることに起因しています。PCOSとT2DMは、生化学的、臨床的、代謝的な特徴を有しています。また、PCOSやT2DMの患者さんの間には高い重複率があります。PCOSが関与するT2DMは、生殖器系に評価的な傷害をもたらす可能性があります。PCOSの患者数が多いほど、市場は拡大します。

一般市民の認識不足が市場成長の妨げとなります。

しかし、医療従事者や患者における高度な知識のギャップが、診断の遅れや治療のばらつきの原因となっています。また、患児女性にとって、エビデンスに基づく利用しやすい情報が少ないことが不満につながります。多くの女性は排卵を知らないため、診断情報が乱れ、不妊の原因となり、様々な健康リスクと結びついています。

COVID-19のインパクト分析

COVID-19の登場は、世界の排卵障害診断市場にかなりのインパクトを与えました。2020年7月にBMC Medicineに掲載された論文によると、生殖年齢の女性において、多嚢胞性卵巣症候群（PCOS）は最も頻度の高い内分泌疾患を構成し、有病率は10～15％に達するかそれを超える可能性もあるそうです。そのため、COVID-19に感染する可能性が高くなります。一方、パンデミック時には、交通機関の制限や封鎖により、多くの患者さんが通常の治療を受けることが困難な状況に陥りました。パンデミック時には多くの産業がロックダウンされ、市場に悪影響を及ぼしました。

しかし、2021年ではなく2022年半ばには状況が好転するため、病院で治療を受けることができるようになります。この市場も予測期間には良好な成長を見せると思われます。

世界の排卵障害診断市場レポートでは、約65以上の市場データ表、65以上の図表、200ページ以上（概算）の範囲でのアクセスを提供することになります。

目次

第1章 市場調査手法とスコープ

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

  • 排卵障害別市場内訳
  • 診断別市場内訳
  • エンドユーザー別市場内訳
  • 地域別市場内訳

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 肥満率の上昇
      • 糖尿病罹患率の増加
    • 抑制要因
      • 診断の認知度の低さ
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 法規制分析
  • プライシング分析
  • アンメットニーズ分析

第6章 COVID-19分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、あるいは将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 排卵障害別

  • 多嚢胞性卵巣症候群
  • 高プロラクチン血症
  • 黄体期不全
  • 視床下部機能障害
  • 腫瘍
  • 自己免疫性卵巣炎
  • 原発性卵巣機能不全
  • 抵抗性卵巣症候群
  • その他

第8章 診断別

  • ホルモンの臨床検査
  • 下垂体および視床下部のCTスキャンおよびMRIスキャン
  • 卵巣生検
  • その他

第9章 エンドユーザー別

  • 病院
  • 婦人科クリニック
  • 診断センター
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 治療タイプ別ベンチマーク

第12章 企業プロファイル

  • Siemens Healthcare
    • 企業概要
    • 治療タイプのポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • GE Healthcare
  • Fujifilm Holdings
  • Swiss Precision Diagnostics
  • Toshiba Medical Systems Corporation
  • Carestream Health
  • Genova Diagnostics
  • Quest Diagnostics
  • LabCorp
  • Esaote

第13章 排卵障害診断の世界市場-DataM

目次
Product Code: DMCD803

Market Overview

Ovulation Disorder Diagnosis Market size was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 5.8% during the forecast period (2022-2029).

Ovulation disorders are the main source of infertility in women or girls. Ovulation disorders are disturbances in the production of an egg during a woman's menstrual cycle. The disorders often occur due to hypothalamic dysfunction, premature ovarian failure and polycystic ovary syndrome.

Market Dynamics

The ovulation disorder diagnosis market growth is driven by the rising adoption of planned pregnancies, a decrease in fertility rate along with increasing awareness of different ovulation disorders among the public

The prevalence of polycystic ovary syndrome (PCOS) in patients with type 2 diabetes is expected to drive the market growth

Polycystic ovary syndrome (PCOS) is a common metabolic and endocrine reproductive disease associated with cardiovascular, metabolic, and psychological factors affecting around 7% of women globally. As per the article published in Frontiers in Endocrinology in August 2022, Diabetes mellitus (DM) is a global public health concern. Around 537 million adults (20-79 years old) worldwide have developed DM in 2021, mostly in the younger age group. Now, more patients are developing type 2 DM (T2DM) at a younger age, and women with T2DM are affected more often during the reproductive period. Reproductive dysfunction in women patients with T2DM is cautiously increasing. Compared with patients without T2DM, patients with T2DM show more clinical changes, such as menstrual disorders and polycystic ovaries. This may be associated with the rise in cellular androgen levels induced by the cooperation of luteinizing hormone and insulin.

In addition, PCOS results from ovarian granulosa cells' stimulation by endogenous insulin resistance in type 2 diabetes and hyperinsulinem, which promote the growth and number of small follicles. PCOS and T2DM have biochemical, clinical, and metabolic characteristics. There is also a high overlap rate between patients with PCOS or T2DM. T2DM involved by PCOS may result in evaluative injuries to the reproductive system. The more patients with PCOS drive the market.

The lack of awareness in public will hamper the growth of the market

However, advanced knowledge gaps among health professionals and patients contribute to diagnostic delays and variation in care. In addition, a dearth of evidence-based, accessible information for affected women leads to dissatisfaction. Many women are unaware of ovulation, which disorders diagnosis information and causes infertility and is linked with various health risks.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global ovulation disorder diagnosis market. As per the article published in BMC Medicine in July 2020, in women of reproductive age, polycystic ovary syndrome (PCOS) constitutes the most frequent endocrine disorder, with a prevalence that may reach or even exceed 10-15%. The more chances are there of getting infected from COVID-19. On the other hand, many patients faced difficulty receiving their regular treatments during the pandemic due to transportation restrictions and lockdowns. Many industries are locked down in the pandemic, which negatively impacts the market.

However, because the situation is reversing in the middle of 2022 rather than 2021, the patient can now receive treatment in the hospital. The market will also show good growth in the forecast period.

Segment Analysis

The polycystic ovarian syndrome segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The polycystic ovarian syndrome segment is expected to boost the market over the period of the forecast. In some cases, a female doesn't make enough of the hormones required to ovulate. When ovulation doesn't happen, the ovaries develop many small cysts. These cysts generate hormones called androgens. Females with PCOS often have high levels of androgens. This results in more problems with a woman's menstrual cycle and can cause many symptoms of PCOS. If anyone has irregular periods and higher levels of androgen shown in blood tests, these women have PCOS. According to the Cleveland Clinic, PCOS is very common; up to 15% of women of reproductive age have it. Women not diagnosed and treated for PCOS may be at risk for developing conditions that raise the risk of cardiovascular disease, including obesity, high blood pressure, gestational diabetes, and high cholesterol. Therefore, diagnosing PCOS is important and increasing cases of PCOS lead to increasing demand for the diagnosis market. There's no single test specifically diagnosing polycystic ovary syndrome (PCOS). The healthcare professionals suggested a pelvic exam, blood tests, and ultrasound.

Geographical Analysis

North America region holds the largest market share of the global ovulation disorder diagnosis market

North America dominates the market for ovulation disorder diagnostics and is expected to show a similar trend over the forecast period. It is anticipated to hold a significant market size over the forecast period (2022-2029) owing to advanced healthcare infrastructure and rising awareness in public regarding ovulation disorder diagnosis. According to the Centers for Disease Control and Prevention, PCOS is one of the most common causes of female infertility, affecting 6% to 12% (as many as 5 million) of US women of reproductive age. The cases of PCOS and increasing health awareness in women drive the market in the North American region. In addition, the key players are adopting market strategies such as mergers and new launches of the product. For instance, in December 2021, Labcorp acquired the Toxikon Corporation, a contract research organization delivering best-in-class nonclinical testing services. Adding Toxikon to Labcorp Drug Development bolsters Labcorp's strong nonclinical development portfolio.

Competitive Landscape

The ovulation disorder diagnosis market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Siemens Healthcare, GE Healthcare, Fujifilm Holdings, Swiss Precision Diagnostics, Toshiba Medical Systems Corporation, Carestream Health, Genova Diagnostics, Quest Diagnostics, LabCorp, and Esaote, among others. The major players are adopting several growth strategies such as Treatment type launches, acquisitions, and collaborations, which are contributing to the growth of the ovulation disorder diagnosis market globally.

For instance,

  • In July 2022, Canon Medical Systems USA Inc. acquired NXC Imaging, a medical imaging equipment distributor and service provider headquartered in Minneapolis, Minnesota.

Toshiba Medical Systems Corporation (TMSC)

Overview:

TMSC is a company which is manufactured, sells, and provisions technical services for medical equipment, including diagnostic x-ray systems, medical x-ray CT systems, magnetic resonance imaging systems (MRI), computed tomography (CT) diagnostic ultrasound systems, radiation therapy systems, and others.

Treatment type Portfolio:

Computed Tomography: The system provides new clinical values such as functional diagnosis and dynamic observation apart from conventional morphological. Also able to provide 160 mm-wide coverage of 3D imaging in one rotation with 0.35 seconds, and it is patient-friendly medical care and requires less scanning time and exposure dose.

The global ovulation disorder diagnosis market report would provide access to approximately 65+ market data tables, 65+ figures, and in the range of 200+ (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet By Ovulation Disorders
  • 3.2. Market Snippet By Diagnosis
  • 3.3. Market Snippet By End-users
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising obesity rates
      • 4.1.1.2. The increasing prevalence of diabetes
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of awareness of diagnosis
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Ovulation Disorders

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
    • 7.1.2. Market Attractiveness Index, By Ovulation Disorders
  • 7.2. Polycystic Ovarian Syndrome*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Hyperprolactinemia
  • 7.4. Luteal Phase Defect
  • 7.5. Hypothalamus Dysfunction
  • 7.6. Tumors
  • 7.7. Autoimmune Oophoritis
  • 7.8. Primary Ovarian Failure
  • 7.9. Resistant Ovary Syndrome
  • 7.10. Others

8. By Diagnosis

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 8.1.2. Market Attractiveness Index, By Diagnosis
  • 8.2. Laboratory Testing of Hormones*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. CT Scan and MRI Scan of The Pituitary Gland and Hypothalamus
  • 8.4. Ovarian Biopsy
  • 8.5. Others

9. By End-users

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 9.1.2. Market Attractiveness Index, By End-users
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Gynecological Clinics
  • 9.4. Diagnostic Centers
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 10.4.6.
    • 10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Treatment type Benchmarking

12. Company Profiles

  • 12.1. Siemens Healthcare*
    • 12.1.1. Company Overview
    • 12.1.2. Treatment type Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. GE Healthcare
  • 12.3. Fujifilm Holdings
  • 12.4. Swiss Precision Diagnostics
  • 12.5. Toshiba Medical Systems Corporation
  • 12.6. Carestream Health
  • 12.7. Genova Diagnostics
  • 12.8. Quest Diagnostics
  • 12.9. LabCorp
  • 12.10. Esaote

LIST NOT EXHAUSTIVE

13. Global Ovulation Disorder Diagnosis Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us